Boston Scientific (BSX) lost nearly 6% in the premarket on Wednesday despite reporting better-than-expected Q2 2026 financials as the medical device maker set its Q3 and full-year earnings outlook ...
Original Image Link
Source:www.msn.com
Original Image Link
Source:www.msn.com
Posted: 2026-07-29 05:55:47
















